Advaxis (ADXS) announced positive results from its Phase 1/2 study using ADXS-503 to treat patients with non-small cell lung cancer (NSCLC). These results were presented at a medical conference. They were preliminary results, but nonetheless were still impressive as these patients were heavily pre-treated after having failed multiple prior therapies. The biotech had also reported an update on its survival data for its ADXS-PSA metastatic castration-resistant prostate cancer (mCRPC) drug. It had seen a big jump in median overall survival from its initial report of 22 months from last year. Now, median overall